This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Centene Continues to Capitalize on Obamacare and So Will You

Stocks in this article: CNCMOHHNTCNCIHF

NEW YORK (TheStreet) -- Centene (CNC) is in the health care sweetspot thanks to being part of one of the leading industry groups this year, health care providers.

Centene shares, at $80, are up 35% for the year to date.

Concerns about the launch of the Affordable Care Act, aka Obamacare, sent these stocks into a tailspin at first, but most of these stocks have since regained ground over the last few months as investors realize the growth potential.

Read More: The Story Behind Sarepta's Firing of Its Top Scientist

There continues to be conflicting court rulings surrounding the legality of Obamacare subsidies, but in the absence of a U.S. Supreme Court decision, the provider stocks appear to be shrugging off these lower court rulings.


Data from Best Stocks Now App

Centene provides programs and related services to address the needs of the under-insured and uninsured individuals. It offers Medicaid and Medicaid-related coverage to individuals through government subsidized programs and operates in 21 states.

As a result of the Affordable Care Act, an additional six million Americans have enrolled in Medicaid and related health programs for the poor through the end of April. More people are now eligible for state Medicaid programs and many of these states are expanding their programs and contracting with private health insurance companies like Molina (MOH), Health Net (HNT) and Centene. Medicaid is now a growth story and these companies are the beneficiaries.

Earnings Results

On Tuesday, Centene reported strong second-quarter earnings results of 95 cents vs. the consensus of 72 cents. Revenue of $3.74 billion also beat the consensus estimate of $3.65 billion. The company guided up this year's earnings to a range of $3.70-$3.90 vs. prior guidance of $3.60-$3.90 and the consensus of $3.73.

Read More: Gilead Sovaldi $3.5 Billion: The Most Important Number in Biotech Earnings Season

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,461.32 -153.49 -0.92%
S&P 500 1,927.11 -14.17 -0.73%
NASDAQ 4,382.8470 -36.6310 -0.83%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs